IVVD vs. GLUE, AVXL, PSTX, CADL, SOPH, ADAP, STRO, CRBU, JSPR, and FENC
Should you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Monte Rosa Therapeutics (GLUE), Anavex Life Sciences (AVXL), Poseida Therapeutics (PSTX), Candel Therapeutics (CADL), SOPHiA GENETICS (SOPH), Adaptimmune Therapeutics (ADAP), Sutro Biopharma (STRO), Caribou Biosciences (CRBU), Jasper Therapeutics (JSPR), and Fennec Pharmaceuticals (FENC). These companies are all part of the "biological products, except diagnostic" industry.
Invivyd (NASDAQ:IVVD) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment.
Monte Rosa Therapeutics' return on equity of -74.13% beat Invivyd's return on equity.
In the previous week, Invivyd had 5 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 11 mentions for Invivyd and 6 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.80 beat Invivyd's score of 0.44 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.
Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
Invivyd has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
Monte Rosa Therapeutics received 3 more outperform votes than Invivyd when rated by MarketBeat users. However, 60.00% of users gave Invivyd an outperform vote while only 37.50% of users gave Monte Rosa Therapeutics an outperform vote.
70.4% of Invivyd shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 17.9% of Invivyd shares are held by insiders. Comparatively, 5.3% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Invivyd presently has a consensus price target of $11.33, suggesting a potential upside of 378.20%. Monte Rosa Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 122.22%. Given Invivyd's stronger consensus rating and higher possible upside, research analysts plainly believe Invivyd is more favorable than Monte Rosa Therapeutics.
Summary
Invivyd beats Monte Rosa Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Invivyd News Delivered to You Automatically
Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
